Empliciti Approval History
FDA Approved: Yes (First approved November 30, 2015)
Brand name: Empliciti
Generic name: elotuzumab
Dosage form: Injection
Company: Bristol-Myers Squibb Company and AbbVie
Treatment for: Multiple Myeloma
Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
Development History and FDA Approval Process for Empliciti
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.